[Erlotinib-induced acneiform rash not affecting previously irradiated skin].
Eguren
C
C
Domínguez-Fernández
I
I
Santiago-Sánchez-Mateos
D I
DI
García-Díez
A
A
D017486:Acneiform Eruptions / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D001132:Arm; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride; D005148:Facial Dermatoses / Q000139:chemically induced; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D007825:Laryngectomy; D008297:Male; D008875:Middle Aged; D037981:Neck Dissection; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009928:Organ Specificity; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D011799:Quinazolines / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D018714:Radiotherapy, Adjuvant; D012867:Skin / Q000528:radiation effects; D013909:Thorax
D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors